SCHEMBL19588439

SCHEMBL19588439

CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Cc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 13/20 0.77
▸ FGFR4 P22455 10/20 0.77
▸ FGFR1 P11362 10/20 0.77
▸ FGFR2 P21802 6/20 0.77
▸ LCK P06239 3/20 0.77
▸ JAK2 O60674 2/20 0.77
▸ ABL1 P00519 2/20 0.77
▸ INSR P06213 2/20 0.77
▸ FYN P06241 2/20 0.77
▸ YES1 P07947 2/20 0.77
▸ LYN P07948 2/20 0.77
▸ RET P07949 2/20 0.77
▸ MET P08581 2/20 0.77
▸ ROS1 P08922 2/20 0.77
▸ KIT P10721 2/20 0.77
▸ SRC P12931 2/20 0.77
▸ BRAF P15056 2/20 0.77
▸ PDGFRA P16234 2/20 0.77
▸ FLT1 P17948 2/20 0.77
▸ TYK2 P29597 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Infigratinib SCHEMBL374435 0.87 FGFR3 (1.00) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL2013451 0.84 FGFR3 (0.91) FGFR3FGFR4FGFR1FGFR2LCK
Infigratinib SCHEMBL14893408 0.84 FGFR3 (1.00) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL2011033 0.84 FGFR3 (0.91) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL19338005 0.84 FGFR3 (0.91) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL16383021 0.83 FGFR3 (0.92) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL19952869 0.83 FGFR3 (0.73) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL23281490 0.83 FGFR3 (0.91) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL19848824 0.83 FGFR3 (0.84) FGFR3FGFR4FGFR1FGFR2LCK
SCHEMBL12596389 0.83 FGFR3 (0.91) FGFR3FGFR4FGFR1FGFR2LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815898-B2 Antibody molecules to PD-1 and uses thereof NOVARTIS AG (CH) 2017-11-14 — — US disclosed
US-9815898-B2 Antibody molecules to PD-1 and uses thereof NOVARTIS AG (CH) 2017-11-14 — — US disclosed
Send feedback